GLP-1 drugs revolutionize weight loss: sales expected to reach $100 billion by 2030
Public interest in the GLP-1 class of drugs has skyrocketed, surpassing traditional weight loss methods in Google searches. This is clear evidence of change in the weight loss industry. The glucagon-like peptide-1 (GLP-1) hormone plays a pivotal role in regulating hunger by stimulating insulin release, blocking excess glucagon, and slowing the process of stomach emptying. . This series of actions reduces food consumption and increases satiety.
GLP-1 drugs: new frontrunners in weight management
This class of drugs includes names such as Semaglutide, sold by Novo Nordisk under the Ozempic and Wegovy labels, and Eli Lilly’s Tirzepatide, sold as Mounjaro and Zepbound. Structure Therapeutics has recently gained attention for its oral GLP-1 combination, which has shown positive results in preliminary trials.
Public interest in GLP-1 drugs is rapidly increasing
Analysis by GarageGymReviews reveals that starting in Q1 2022, Google is searching for: GLP-1 weight loss drug Compared to traditional methods such as diet and exercise, which decreased by 26%, it increased by 13.7 times. There is speculation that GLP-1 drugs may soon be used in gym fitness programs, but the fitness industry remains divided on the issue.
GLP-1 drugs: On the rise in U.S. households
About 11 percent of U.S. households have someone who regularly uses GLP-1 drugs, and another 17 percent are considering them, according to a Morgan Stanley report. Capital Group predicts that the total market size for GLP-1 drugs will exceed 2 billion people, and that annual sales will reach a staggering $100 billion by 2030. doing.
In a parallel development, researchers at Stanford University collaborated with Novo Nordisk to develop an innovative drug delivery system. This system (a combination of a biomimetic hydrogel carrier and his GLP-1 receptor agonist) prolongs the action of the drug by about six weeks. The drug, tested in diabetic rats, has the potential to revolutionize the treatment of type 2 diabetes by reducing the frequency of injections to once every four months.